ANA
LLUCH HERNANDEZ
EMÉRITO/A UNIVERSIDAD
Fondazione IRCCS Istituto Nazionale dei Tumori
Milán, ItaliaPublicacións en colaboración con investigadores/as de Fondazione IRCCS Istituto Nazionale dei Tumori (10)
2016
2015
-
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial
Annals of Oncology, Vol. 26, Núm. 12, pp. 2429-2436
2014
-
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
The Lancet Oncology, Vol. 15, Núm. 6, pp. 640-647
2012
-
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial
The Lancet Oncology, Vol. 13, Núm. 1, pp. 25-32
-
Pathological complete response rates following different neoadjuvant chemotherapy regimens for Operable Breast Cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)
Breast Cancer Research and Treatment, Vol. 132, Núm. 3, pp. 843-851
-
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: Activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer
Journal of Clinical Oncology, Vol. 30, Núm. 14, pp. 1594-1600
2011
-
Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study
European Journal of Surgical Oncology, Vol. 37, Núm. 10, pp. 856-863
2010
-
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
The Lancet, Vol. 375, Núm. 9712, pp. 377-384
2008
-
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
Annals of Oncology, Vol. 19, Núm. 6, pp. 1090-1096
2005
-
Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy
Clinical Cancer Research, Vol. 11, Núm. 24, pp. 8715-8721